Jasmin Khateeb1, Eyal Fuchs2, Mogher Khamaisi3. 1. Department of Internal Medicine D, Rambam Health Care Campus, Haifa, Israel. 2. Pulmonary Division, Rambam Health Care Campus, Haifa, Israel; Department of Internal Medicine C, Rambam Health Care Campus, Haifa, Israel. 3. Department of Internal Medicine D, Rambam Health Care Campus, Haifa, Israel; Faculty of Medicine - Technion - Israel Institute of Technology, Haifa, Israel; Division of Endocrinology, Diabetes and Metabolism, Haifa, Israel.
Abstract
BACKGROUND: Diabetes mellitus is a systemic disorder associated with inflammation and oxidative stress which may target many organs such as the kidney, retina, and the vascular system. The pathophysiology, mechanisms, and consequences of diabetes on these organs have been studied widely. However, no work has been done on the concept of the lung as a target organ for diabetes and its implications for lung diseases. AIM: In this review, we aimed to investigate the effects of diabetes and hypoglycemic agent on lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, pulmonary hypertension, and lung cancer. We also reviewed the potential mechanisms by which these effects may affect lung disease patients. RESULTS: Our results suggest that diabetes can affect the severity and clinical course of several lung diseases. CONCLUSIONS: Although the diabetes-lung association is epidemiologically and clinically well-established, especially in asthma, the underlying mechanism and pathophysiology are not been fully understood. Several mechanisms have been suggested, mainly associated with the pro-inflammatory and proliferative properties of diabetes, but also in relation to micro- and macrovascular effects of diabetes on the pulmonary vasculature. Also, hypoglycemic drugs may influence lung diseases in different ways. For example, metformin was considered a potential therapeutic agent in lung diseases, while insulin was shown to exacerbate lung diseases; this suggests that their effects extend beyond their hypoglycemic properties.
BACKGROUND: Diabetes mellitus is a systemic disorder associated with inflammation and oxidative stress which may target many organs such as the kidney, retina, and the vascular system. The pathophysiology, mechanisms, and consequences of diabetes on these organs have been studied widely. However, no work has been done on the concept of the lung as a target organ for diabetes and its implications for lung diseases. AIM: In this review, we aimed to investigate the effects of diabetes and hypoglycemic agent on lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, pulmonary hypertension, and lung cancer. We also reviewed the potential mechanisms by which these effects may affect lung disease patients. RESULTS: Our results suggest that diabetes can affect the severity and clinical course of several lung diseases. CONCLUSIONS: Although the diabetes-lung association is epidemiologically and clinically well-established, especially in asthma, the underlying mechanism and pathophysiology are not been fully understood. Several mechanisms have been suggested, mainly associated with the pro-inflammatory and proliferative properties of diabetes, but also in relation to micro- and macrovascular effects of diabetes on the pulmonary vasculature. Also, hypoglycemic drugs may influence lung diseases in different ways. For example, metformin was considered a potential therapeutic agent in lung diseases, while insulin was shown to exacerbate lung diseases; this suggests that their effects extend beyond their hypoglycemic properties.
Authors: M K Miller; J H Lee; P D Blanc; D J Pasta; S Gujrathi; H Barron; S E Wenzel; S T Weiss Journal: Eur Respir J Date: 2006-07-26 Impact factor: 16.671
Authors: Manuel A R Ferreira; Melanie C Matheson; David L Duffy; Guy B Marks; Jennie Hui; Peter Le Souëf; Patrick Danoy; Svetlana Baltic; Dale R Nyholt; Mark Jenkins; Catherine Hayden; Gonneke Willemsen; Wei Ang; Mikko Kuokkanen; John Beilby; Faang Cheah; Eco J C de Geus; Adaikalavan Ramasamy; Sailaja Vedantam; Veikko Salomaa; Pamela A Madden; Andrew C Heath; John L Hopper; Peter M Visscher; Bill Musk; Stephen R Leeder; Marjo-Riitta Jarvelin; Craig Pennell; Dorret I Boomsma; Joel N Hirschhorn; Haydn Walters; Nicholas G Martin; Alan James; Graham Jones; Michael J Abramson; Colin F Robertson; Shyamali C Dharmage; Matthew A Brown; Grant W Montgomery; Philip J Thompson Journal: Lancet Date: 2011-09-10 Impact factor: 79.321
Authors: Álmos Schranc; Gergely H Fodor; Roberta Südy; József Tolnai; Barna Babik; Ferenc Peták Journal: Front Physiol Date: 2022-06-06 Impact factor: 4.755